Hunter Shkolnik on Invokana Plaintiff Executive Committee

The firm is representing many victims who were prescribed Invokana.

We are proud to announce that Partner Hunter J. Shkolnik has been named as a Plaintiffs’ Executive Committee Member in In Re: Invokana (Canagliflozin) Products Liability Litigation (MDL No. 2750) United Stated District Judge Brian R. Martinotti of the United States District Court of New Jersey.

The Court reviewed all the submissions but ultimately made his decision to assemble and “effective committee” by appointing “an array of highly skilled counsel with diverse backgrounds.” Mr. Shkolnik’s experience handling complex pharmaceutical litigation certainly falls into these parameters.

As a member of the Executive Committee, Mr. Shkolnik will continue to investigate and develop the claims while also overseeing the coordination, preparation, and presentation of the necessary legal documentation.

In 2015 the FDA strengthened its warning based on additional serious safety concerns and added a new Warning and Precaution label. The litigation alleges that the use of Invokana can lead to an increased risk of kidney failure and heart attacks.

“I welcome the opportunity to work with the members of this Executive Committee, People believe that they are taking a drug to treat one disease and end up having to deal with a whole new set up serious health issues. My firm and I are believe that those responsible for our client’s suffering should be held accountable and we are ready to take on that fight.”
Hunter Shkolnik

Other medications along with Invokana are associated with injury and side effects . These include, but aren’t limited to:

  • An excessive amount of acidity in the blood (ketoacidosis);
  • Larger risk of bone fractures;
  • Reduced nutrient bone density;
  • Kidney problems;
  • Heart strikes;
  • High cholesterol levels (hyperkalemia);
  • Vaginal yeast infections;
  • Urinary tract diseases; and
  • Low blood glucose.

The health dangers could lead to death in extreme circumstances, and above are severe. Along with Invokana, the dangers of additional sodium-glucose cotransporter-2 (SGLT2s) medications are being researched.

In case you have taken alternative drugs that are SGLT2 or Invokana and think that you have suffered injury which you wouldn’t have incurred but for your medication, you can have a cause of action against the drug maker. However, so as to get damages, you’ll need to establish that Janssen Pharmaceuticals violated its obligation to the user by distributing and fabricating a defective drug or failing to give sufficient warning of known dangers, andwhich you suffered injury as a direct outcome. A lawyer will be able to assist you to establish the above.

Watch an informational video concerning Invokana.